International Edition
Latest News
Health

STREAM Trial Finds Stopping Statins at 70 Meets Non-Inferiority but Raises Heart Attacks, Strokes

Stopping a daily cholesterol pill after age 70 met a statistical test for non-inferiority in a clinical trial published on November 7, 2026, but the data revealed more heart attacks and strokes among patients who discontinued the therapy.…

STREAM Trial Finds Stopping Statins at 70 Meets Non-Inferiority but Raises Heart Attacks, Strokes

Stopping a daily cholesterol pill after age 70 met a statistical test for non-inferiority in a clinical trial published on November 7, 2026, but the data revealed more heart attacks and strokes among patients who discontinued the therapy.

According to Medicina e Paziente, the international randomized trial named STREAM was presented at the Scientific Sessions 2026 of the American Heart Association and published in the New England Journal of Medicine.

The study evaluated 1,880 people aged 70 or older with an average age of 77.5 years, where 46.9% were women according to Mondosanità, while Medico e paziente reported 46%.

Conducted between November 2021 and April 2026 across 24 clinical centers in Switzerland, France, and the Netherlands, the trial examined participants taking statins for primary prevention who had no known cardiovascular disease but lived with at least two chronic conditions. Among them, 938 participants were assigned to stop taking statins and other lipid-lowering drugs, while 942 continued taking them.

At the end of two years, patients who stopped therapy lived an average of two weeks less without major events compared to those who continued. Because researchers had set the maximum acceptable margin at 5.2 weeks, the trial formally met the statistical criterion for non-inferiority.

However, during a median follow-up of 103 weeks, 119 out of 938 individuals in the suspension group experienced a major event or died, compared to 87 out of 942 individuals in the continuation group, creating an absolute difference of 3.5 percentage points, according to Mondosanità.

Medico e paziente added that in a subsequent follow-up extending up to four years after deprescription, a modest increase in cardiovascular events emerged, while suspension produced no significant advantages in quality of life, muscle pain, falls, or sarcopenia.

About the author: Health Desk

Health Desk at Archynewsy.